Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome, Inc. (Nasdaq: IMNM) reported its Q1 2022 financial results, highlighting FDA clearance for its Phase 1b clinical trial of the COVID-19 antibody cocktail, IMM-BCP-01. This therapy aims to address the urgent need for effective COVID-19 treatments amid new variants. The company also progresses its IL-38 targeting antibody treatment, IMM-ONC-01, with an IND submission planned for late 2022. Financially, R&D expenses were $8.1 million, G&A expenses were $3.6 million, and a net loss of $11.7 million was recorded. Cash reserves stood at $42.9 million as of March 31, 2022.
Immunome, Inc. (Nasdaq: IMNM) has received a safe-to-proceed notification from the U.S. FDA for its IMM-BCP-01 investigational new drug application, allowing progress towards a Phase 1b clinical trial. The company’s antibody cocktail has shown promising in vitro efficacy against the Omicron variant of COVID-19, neutralizing it with significantly higher potency than existing treatments. Financially, Immunome reported a net loss of $7.9M for Q4 2021, with cash reserves of $49.2M as of December 31, 2021. Ongoing projects include the development of IMM-ONC-01 for targeting IL-38 in oncology.
Immunome, Inc. (NASDAQ: IMNM) has announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for the antibody cocktail IMM-BCP-01, aimed at treating COVID-19. The hold was previously placed due to requests for additional information regarding the drug's preparation and administration. Immunome provided a comprehensive report to address these concerns. The company plans to initiate a placebo-controlled dose escalation study for IMM-BCP-01, which utilizes a three-antibody cocktail targeting the SARS-CoV-2 Spike protein.
Immunome (NASDAQ: IMNM) announced positive in vitro results for its antibody cocktail against the SARS-CoV-2 Omicron variant, demonstrating comparable potency to GSK/Vir's sotrovimab. The tests conducted at Boston University and Washington University confirmed that the combination of IMM20253 and IMM20184 neutralized Omicron with an IC50 of 27 nM. The cocktail employs a novel mechanism that enhances viral resistance, targeting the spike protein's ACE2 binding site. Moving forward, Immunome plans to advance its program into Phase 1b trials, supported by funding from the U.S. Department of Defense.
Immunome has received a clinical hold letter from the FDA regarding its IND submission for IMM-BCP-01, a three-antibody cocktail for COVID-19. The FDA has requested additional information about the cocktail's preparation and administration at clinical sites. Immunome intends to provide this information promptly and is still on track to report top-line clinical data for IMM-BCP-01 within the first half of 2022. Additionally, external laboratory tests for the cocktail's efficacy against the Omicron variant are expected this month.
Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat hosted by Cantor Fitzgerald's Brian Cheng on December 8, 2021, at 1:00 p.m. ET, aimed at institutional clients. The event will be accessible via webcast, with a replay available on Immunome's website for 30 days following the live presentation.
Immunome utilizes its proprietary human memory B cell platform to develop innovative antibody therapeutics focusing on oncology and infectious diseases, including COVID-19.
Immunome expects its antibody cocktail, IMM-BCP-01, to be effective against the Omicron variant of SARS-CoV-2. The company is performing laboratory testing to confirm this, with results anticipated in January 2022. IMM-BCP-01 targets three distinct epitopes, enhancing its potential resilience against mutations. The cocktail approach aims to improve viral neutralization, as demonstrated in preclinical tests against other variants. Immunome is advancing IMM-BCP-01 towards clinical trials, pending regulatory approval.
Immunome, Inc. (NASDAQ: IMNM) has submitted an Investigational New Drug (IND) application to the U.S. FDA for IMM-BCP-01, a novel three-antibody cocktail targeting SARS-CoV-2. This submission marks a significant milestone for Immunome as they prepare to conduct clinical studies. Preclinical testing shows that IMM-BCP-01 effectively reduces viral load and encompasses broad coverage against various COVID-19 variants. The project is funded by the U.S. Department of Defense, emphasizing its public health importance as COVID-19 continues to pose a threat.
Immunome, Inc. (Nasdaq: IMNM) made progress in its antibody development, notably with IMM-BCP-01, targeting SARS-CoV-2 variants Lambda and Delta Plus. The company plans to submit an IND for IMM-BCP-01 this quarter, alongside anticipated topline data in H1 2022. Financially, for Q3 2021, R&D expenses reached $4.5M, while G&A expenses were $3.2M, leading to a net loss of $7.7M. As of September 30, 2021, cash reserves stood at $56.3M, indicating sufficient resources for ongoing projects.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company specializing in first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Stifel Healthcare Conference on November 15, 2021, at 8:00 a.m. ET. Interested listeners can access the live audio webcast via the Investor Relations section of Immunome's website, with a replay available for 30 days post-event. Immunome focuses on developing therapies for oncology and infectious diseases, including COVID-19, leveraging its proprietary human memory B cell platform.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
